by: Parent Project Muscular Dystrophy
Avidity Biosciences recently joined PPMD for a community webinar to share topline data from their EXPLORE44® clinical trial, which is assessing the safety and efficacy of the investigational therapy delpacibart zotadirsen (formerly AOC 1044, abbreviated as del-zota) in people living with Duchenne who are amenable to exon 44 skipping. The Avidity team shared background information about del-zota and the EXPLORE44 study, provided an overview of results, and shared insights on next steps for del-zota with regards to BLA submission and FDA approval. The webinar concluded with Avidity answering questions from the community.
